GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Cash, Cash Equivalents, Marketable Securities

Pharos IBio Co (XKRX:388870) Cash, Cash Equivalents, Marketable Securities : ₩17,218.34 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Cash, Cash Equivalents, Marketable Securities?

Pharos IBio Co's quarterly cash, cash equivalents, marketable securities declined from Mar. 2024 (₩22,356.16 Mil) to Jun. 2024 (₩19,514.81 Mil) but then stayed the same from Jun. 2024 (₩19,514.81 Mil) to Sep. 2024 (₩17,218.34 Mil).

Pharos IBio Co's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (₩23,812.30 Mil) to Dec. 2022 (₩15,079.21 Mil) but then increased from Dec. 2022 (₩15,079.21 Mil) to Dec. 2023 (₩25,486.76 Mil).


Pharos IBio Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Pharos IBio Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Cash, Cash Equivalents, Marketable Securities Chart

Pharos IBio Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
4,502.07 14,807.25 23,812.30 15,079.21 25,486.76

Pharos IBio Co Quarterly Data
Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only 27,738.96 25,486.76 22,356.16 19,514.81 17,218.34

Pharos IBio Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Pharos IBio Co  (XKRX:388870) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Pharos IBio Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharos IBio Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co Headlines

No Headlines